why choose us

First received: September 13, 2023

Clinical Trial: Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Triple Negative Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies

Brief Summary: A first-in-human study using BDC-3042 as a single agent and in combination with pembrolizumab in patients with advanced malignancies

Read more